LifeMD (NASDAQ: LFMD) posts Q2 $47.3M revenue, cuts 2026 guidance

Q: What were LifeMD (LFMD)'s key financial results for Q2 2026?

LifeMD generated $47.3 million in Q2 2026 telehealth revenue, down 4% year-over-year, with 89% gross margin. GAAP net loss from continuing operations attributable to common stockholders was $7.9 million , or $0.16 per share, and adjusted EBITDA was a $3.5 million loss.

Q: How did LifeMD (LFMD)'s subscriber base change in Q2 2026?

Active subscribers increased 20% year-over-year to approximately 355,671 at June 30, 2026. Weight Management Program subscribers reached about 108,000 , and around 84% of revenue came from recurring subscriptions, reflecting growth in longer-duration membership plans.

Q: What is LifeMD (LFMD)'s cash and debt position after Q2 2026?

LifeMD ended Q2 2026 with $25.1 million in cash and no debt , plus an undrawn $30 million revolving credit facility. Management highlighted this liquidity and reduced marketing spend as supporting an expectation that cash will build through year-end.

Q: How has LifeMD (LFMD) updated its 2026 financial guidance?

For full-year 2026, LifeMD now expects revenue of $205.5–$212.5 million , down from $220–$230 million , and adjusted EBITDA of -$6.0 million to breakeven , down from $12–$17 million . Q3 2026 guidance is revenue of $48–$51 million and adjusted EBITDA of -$1 million to $2 million .

Q: When does LifeMD (LFMD) expect to return to positive adjusted EBITDA?

Management expects a return to positive adjusted EBITDA in the second half of 2026. Fourth-quarter 2026 guidance of $60–$64 million revenue and $3–$6 million adjusted EBITDA implies an annualized revenue run rate of about $250 million and roughly $22 million of annualized adjusted EBITDA before XYOSTED launch costs.

Q: What strategic shifts is LifeMD (LFMD) making in its business model?

LifeMD is transitioning weight-management patients to branded GLP-1 therapies , emphasizing multi-month subscription packages, expanding Women’s Health, scaling its in-house pharmacy, and launching a telehealth co-marketing collaboration for XYOSTED , while developing pharmaceutical, employer, insurance, Medicare, and enterprise channels.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

LifeMD, Inc. reported Q2 2026 telehealth revenue of $47.3 million, down 4% year-over-year but within guidance, as it shifts weight-management patients to branded GLP-1 therapies and longer-duration subscriptions. Gross margin expanded to about 89%, with roughly 84% of revenue from recurring subscriptions.

Active subscribers rose 20% to about 356,000, including 108,000 in the Weight Management Program. Despite this growth, GAAP net loss from continuing operations attributable to common stockholders widened to $7.9 million, or $0.16 per share, and adjusted EBITDA moved to a loss of about $3.5 million from a profit a year earlier.

LifeMD ended the quarter with $25.1 million of cash, no debt and $30 million of undrawn revolving credit capacity. Management launched a telehealth co-marketing collaboration for XYOSTED and highlighted improving Women’s Health trends.

For Q3 2026 the company guides to $48–$51 million of revenue and adjusted EBITDA between a $1 million loss and $2 million profit, and now expects full-year 2026 revenue of $205.5–$212.5 million and adjusted EBITDA between a $6.0 million loss and breakeven, both reduced from prior guidance.

Positive

Subscriber base grew 20% year-over-year to approximately 356,000 active subscribers, with about 84% of revenue from recurring subscriptions and gross margin at roughly 89%, supporting a more predictable, higher-margin business model.

Negative

Revised 2026 revenue guidance down to $205.5–$212.5 million from $220–$230 million, and adjusted EBITDA outlook to -$6.0 million to breakeven from $12–$17 million, signaling weaker profitability expectations.
Q2 adjusted EBITDA deteriorated to a $3.5 million loss from $3.9 million profit a year earlier, and GAAP net loss from continuing operations attributable to common stockholders more than doubled to $7.9 million.

Filing Explained

By June 30, common shares outstanding had increased, creating a potential ownership dilution effect for existing holders.

A Form 8-K reports specified material events, and this filing reports LifeMD’s completed second-quarter results while furnishing an investor presentation for use beginning August 5.

The balance sheet shows common shares outstanding of $47,820,492 at June 30, 2026, versus $46,656,976 at December 31, 2025; issued shares were $47,923,532 versus $46,760,016.

Because additional shares increase the total share count, this higher reported share count reduces an existing holder’s percentage ownership if other ownership changes do not offset it.

The same balance sheet reports cash of $25,141,615 at June 30, compared with $36,786,318 at December 31, while continuing-operations operating cash flow for the six months was negative $6,481,023; total stockholders’ equity was $7,966,455, versus $23,156,580.

Subsequent balance sheets will show whether the reported common share count continues to increase, which would further affect existing holders’ percentage ownership.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q2 2026 revenue: $47.3 million Q2 2026 gross margin: 89% Active subscribers: 355,671 +5 more

8 metrics

Q2 2026 revenue $47.3 million Telehealth revenue for the three months ended June 30, 2026

Q2 2026 gross margin 89% Gross margin in Q2 2026 versus 86% in Q2 2025

Active subscribers 355,671 Active subscribers at June 30, 2026, up 20% year-over-year

Q2 2026 GAAP net loss (continuing, common) $7.9 million Net loss from continuing operations attributable to common stockholders in Q2 2026

Q2 2026 adjusted EBITDA $(3.5) million Adjusted EBITDA loss for the three months ended June 30, 2026

Cash balance $25.1 million Cash as of June 30, 2026, with no debt and a $30 million undrawn revolver

2026 revenue guidance $205.5–$212.5 million Revised full-year 2026 revenue guidance range

2026 adjusted EBITDA guidance -$6.0 million to breakeven Revised full-year 2026 adjusted EBITDA guidance range

Key Terms

adjusted EBITDA, recurring rebill base, GLP-1, revolving credit facility, +1 more

5 terms

adjusted EBITDA financial

"Adjusted EBITDA loss was approximately $3.5 million, compared with adjusted EBITDA of approximately $3.9 million"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

recurring rebill base financial

"Our recurring rebill base now represents approximately 84% of revenue and is the profit engine"

GLP-1 medical

"transition away from compounded GLP-1 medications and toward branded GLP-1 therapies"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

revolving credit facility financial

"an undrawn $30 million revolving credit facility"

A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.

discontinued operations financial

"WorkSimpli, which was divested on November 4, 2025, and is reported as discontinued operations"

Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.

Earnings Snapshot

Revenue Q2 2026: $47.3 million · Guidance included

Three and six months ended June 30, 2026

Revenue Q2 2026 $47.3 million -4% year-over-year

Gross margin Q2 2026 89% +280 bps vs Q2 2025

GAAP net loss from continuing operations attributable to common $7.9 million vs $3.8 million loss in Q2 2025

Adjusted EBITDA Q2 2026 $(3.5) million vs $3.9 million in Q2 2025

Active subscribers 355,671 up 20% year-over-year

Guidance

For 2026, revenue is guided to $205.5–$212.5 million and adjusted EBITDA to -$6.0 million to breakeven, both reduced from prior guidance of $220–$230 million revenue and $12–$17 million adjusted EBITDA.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 08/05/2026 - 04:11 PM Accepted by SEC EDGAR 08/05/2026 - 04:10 PM

FAQ

What were LifeMD (LFMD)'s key financial results for Q2 2026?

LifeMD generated $47.3 million in Q2 2026 telehealth revenue, down 4% year-over-year, with 89% gross margin. GAAP net loss from continuing operations attributable to common stockholders was $7.9 million, or $0.16 per share, and adjusted EBITDA was a $3.5 million loss.

How did LifeMD (LFMD)'s subscriber base change in Q2 2026?

Active subscribers increased 20% year-over-year to approximately 355,671 at June 30, 2026. Weight Management Program subscribers reached about 108,000, and around 84% of revenue came from recurring subscriptions, reflecting growth in longer-duration membership plans.

What is LifeMD (LFMD)'s cash and debt position after Q2 2026?

LifeMD ended Q2 2026 with $25.1 million in cash and no debt, plus an undrawn $30 million revolving credit facility. Management highlighted this liquidity and reduced marketing spend as supporting an expectation that cash will build through year-end.

How has LifeMD (LFMD) updated its 2026 financial guidance?

For full-year 2026, LifeMD now expects revenue of $205.5–$212.5 million, down from $220–$230 million, and adjusted EBITDA of -$6.0 million to breakeven, down from $12–$17 million. Q3 2026 guidance is revenue of $48–$51 million and adjusted EBITDA of -$1 million to $2 million.

When does LifeMD (LFMD) expect to return to positive adjusted EBITDA?

Management expects a return to positive adjusted EBITDA in the second half of 2026. Fourth-quarter 2026 guidance of $60–$64 million revenue and $3–$6 million adjusted EBITDA implies an annualized revenue run rate of about $250 million and roughly $22 million of annualized adjusted EBITDA before XYOSTED launch costs.

What strategic shifts is LifeMD (LFMD) making in its business model?

LifeMD is transitioning weight-management patients to branded GLP-1 therapies, emphasizing multi-month subscription packages, expanding Women’s Health, scaling its in-house pharmacy, and launching a telehealth co-marketing collaboration for XYOSTED, while developing pharmaceutical, employer, insurance, Medicare, and enterprise channels.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2026

LIFEMD, INC.

(Exact name of Registrant as specified in its charter)

Delaware

001-39785

76-0238453

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

236 Fifth Avenue, Suite 400

New York, NY 10001

(Address of principal executive offices, including zip code)

(866) 351-5907

(Registrant’s telephone number, including area code)

Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	LFMD	The Nasdaq Global Market
8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share	LFMDP	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

The Company hereby furnishes an investor presentation (the “Presentation”), which it expects to use in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others commencing on August 5, 2026. The Presentation is furnished herewith as Exhibit 99.2 and may also be found on the Company’s website at https://lifemd.com.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this Current Report that is required to be disclosed solely by reason of Regulation FD. The information contained in the Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information in this Current Report on Form 8-K (including Exhibits attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K includes information that may constitute forward-looking statements. These forward-looking statements are based on the Company’s current beliefs, assumptions, and expectations regarding future events, which in turn are based on information currently available to the Company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. Forward-looking statements include, without limitation, statements relating to projected industry growth rates, the Company’s current growth rates and the Company’s present and future cash flow position. A variety of factors could cause actual events and results, as well as the Company’s expectations, to differ materially from those expressed in or contemplated by the forward-looking statements. Risk factors affecting the Company are discussed in detail in the Company’s filings with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Item 9.01. Exhibits.

(d) Exhibits

Exhibit No.		Exhibit
99.1		Press Release dated August 5, 2026
99.2		Investor Presentation dated August 5, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		LIFEMD, INC.

Dated:	August 5, 2026	By:	/s/ Atul Kavthekar
			Atul Kavthekar
			Chief Financial Officer

Exhibit 99.1

LifeMD Reports Second Quarter 2026 Results

	●	Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.

	●	Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.

	●	Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy.

	●	Weight Management Program subscribers grew to approximately 108,000 at quarter end; total active subscribers increased 20% year-over-year to approximately 356,000.

	●	Women’s Health operating trends continues to improve, with lower customer acquisition costs and a broad set of new pharmacy products launching in the second half.

	●	Launched an exclusive telehealth co-marketing collaboration with Halozyme’s wholly-owned subsidiary, Antares Pharma, Inc., for XYOSTED®, the only FDA-approved, once-weekly subcutaneous testosterone auto-injector — with additional strategic partnerships and enterprise relationships advancing toward execution in the second half of 2026.

	●	Exited the quarter with $25.1 million of cash, no debt, and $30 million of additional liquidity under its revolving credit facility.

	●	Expecting a return to positive adjusted EBITDA in the second half of 2026 and an expected fourth quarter exit revenue run rate of approximately $250 million and approximately $22 million of annualized adjusted EBITDA

	●	Revising full year 2026 guidance to revenue of $205.5 million to $212.5 million and adjusted EBITDA of negative $6.0 million to breakeven, including $2 million to $3 million of net launch costs for XYOSTED® in 2026.

Conference call begins at 4:30 p.m. Eastern time today

NEW YORK, August 5, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today reported financial results for the second quarter ended June 30, 2026.

Management Commentary

“Revenue of $47.3 million came in within our guidance range, and while adjusted EBITDA finished below the range we guided to, it improved approximately 21% sequentially. Most importantly, we understand the drivers of the result and have already taken steps to improve performance in the second half. At the same time, the quarter included meaningful progress in reshaping the business around longer-duration members, branded therapies, pharmacy, insurance, and new partnerships. The near-term impact on profitability was greater than we anticipated, but the decisions we made during the quarter are already driving a substantial shift towards what we believe will be higher LTV subscribers,” said Justin Schreiber, Chairman and CEO of LifeMD.

“Our model remains simple: Quality Care. Quality Products. Quality Revenue. We are building around longer patient relationships and a more diversified acquisition model, with increasing contributions over time from pharmaceutical manufacturers, employers, insurers, Medicare, referrals, and cross-care within our existing patient base. Following the pricing change in weight management, the share of new patients selecting multi-month packages increased from approximately 25% year to date before the change to approximately 85% after it. We believe these longer-duration relationships can support better outcomes, stronger retention, higher lifetime value, and more predictable revenue over time.

“This transition to branded GLP-1 medications has weighed on near-term profitability, but it has produced a fundamentally stronger company that is more diversified. We are also encouraged by the progress we are seeing in Women’s Health, the launch of XYOSTED® with Halozyme, the continued expansion of our pharmacy, and the development of our pharmaceutical, enterprise, insurance, and Medicare channels. We expect to return to positive adjusted EBITDA in the second half and to exit 2026 at an annualized revenue run rate of approximately $250 million with approximately $22 million of annualized adjusted EBITDA. LifeMD has never been better positioned, and the second half of this year will begin to demonstrate what our expanding platform is capable of,” concluded Mr. Schreiber.

“The second quarter reflected the planned step-down in marketing investment we described on our last call, with selling and marketing expense declining $1.8 million sequentially and other general and administrative expenses declining by approximately $2.2 million,” said Atul Kavthekar, Chief Financial Officer of LifeMD. “Revenue aligned with our expectations in the quarter, and gross margin expanded to approximately 89%, driven by lower shipping and fulfillment costs, improved provider efficiency, and the continued scaling of our in-house pharmacy. Our recurring rebill base now represents approximately 84% of revenue and is the profit engine that funds our growth. We exited the quarter with $25.1 million in cash and no debt, and we amended our revolving credit facility, further strengthening our financial flexibility. As more patients choose longer-duration subscription plans and marketing spend declines in the second half, we expect cash to build through year-end.”

Second Quarter 2026 Financial Highlights

All comparisons are with the second quarter of 2025 on a continuing operations basis (excluding WorkSimpli, which was divested on November 4, 2025, and is reported as discontinued operations for all periods presented). Non-GAAP financial measures referenced below are defined and reconciled to the most directly comparable GAAP measures at the end of this press release.

	●	Total revenue was $47.3 million compared with $49.0 million in the prior-year period, reflecting the continued shift from compounded to branded GLP-1 therapies and lower upfront revenue associated with the Company’s pricing and mix decisions.

	●	Approximately 84% of revenue was derived from recurring subscriptions.

	●	The number of active subscribers increased 20% to approximately 356,000 at quarter end.

	●	At quarter end, the number of Weight Management Program subscribers was approximately 108,000, up from just under 100,000 at the end of the first quarter of 2026.

	●	Gross profit was $42.0 million, essentially flat with the prior-year period despite lower revenue; gross margin expanded to approximately 89%, compared to 86% in the prior-year period, primarily due to lower shipping and fulfillment costs and the continued scaling of the Company’s affiliated pharmacy.

	●	Selling and marketing expenses increased 27% year-over-year to $28.0 million, but declined $1.8 million from the first quarter of 2026, consistent with the planned sequential step-down in patient acquisition spend.

	●	General and administrative expenses declined 5% to $13.6 million, led by lower employee expenses and legal and professional services fees.

	●	GAAP net loss from continuing operations attributable to common stockholders was $7.9 million, or $0.16 per share, compared with a GAAP net loss from continuing operations attributable to common stockholders of $3.8 million, or $0.09 per share, in the prior-year period.

	●	Adjusted EBITDA loss was approximately $3.5 million, compared with adjusted EBITDA of approximately $3.9 million in the prior-year period, reflecting elevated customer acquisition costs earlier in the quarter and lower upfront cash collection associated with the Company’s $39 introductory offer; monthly performance improved as the quarter progressed.

	●	Cash totaled $25.1 million as of June 30, 2026, and the Company had no debt at quarter end, with an undrawn $30 million revolving credit facility.

Second Quarter Key Performance Metrics

($ in 000s)	Three Months Ended June 30,						Y-o-Y
Key Performance Metrics	2026			2025			% Growth

Revenue	$	47,281		$	49,019			-4	%

Gross Profit	$	41,997		$	42,180			0	%

Gross Margin %		89	%		86	%		+280bpts

Adjusted EBITDA	$	(3,530	)	$	3,886			-191	%

Active Subscribers		355,671			296,946			20	%

Positioned for a Strong Second Half

LifeMD enters the second half with improving acquisition trends, a growing recurring patient base, and a broader set of growth channels taking shape. Priorities for the remainder of 2026 include scaling longer-duration weight management memberships, expanding Women’s Health and the XYOSTED® collaboration, increasing pharmacy attachment, and advancing pharmaceutical, insurance, Medicare, employer, and enterprise relationships. Together, these initiatives should reduce reliance on paid media, deepen patient relationships, and support improving operating leverage and financial performance through year-end.

Financial Guidance

For the third quarter of 2026, the Company expects:

	●	Revenue in the range of $48 million to $51 million.

	●	Adjusted EBITDA in the range of negative $1 million to positive $2 million, returning to positive adjusted EBITDA as cost savings take hold and the Company’s recurring rebill base continues to build.

For the full year 2026, the Company expects (revised from previous guidance):

	●	Revenue in the range of $205.5 million to $212.5 million, compared with previous guidance of $220 million to $230 million.

	●	Adjusted EBITDA in the range of negative $6.0 million to breakeven, compared with previous guidance of $12 million to $17 million.

	●	The Company’s fourth quarter 2026 guidance of $60 million to $64 million of revenue and $3 million to $6 million of adjusted EBITDA implies an annualized exit run rate of approximately $250 million of revenue and before estimated XYOSTED® launch costs, approximately $22 million of continuing adjusted EBITDA.

Conference Call

LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:

Toll-free dial-in number:	(800) 715-9871
International dial-in number:	+1 (646) 307-1963
Conference ID:	3616168 (“LifeMD, Inc. Second Quarter 2026 Results”)

A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.

About LifeMD, Inc.

LifeMD^® is a leading virtual care company making high-quality healthcare more accessible, convenient, and affordable. Through its vertically integrated platform, LifeMD connects patients with a 50-state affiliated medical group, laboratory services, a state-of-the-art in-house pharmacy, and a U.S.-based patient care center. Together, these capabilities support care across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. For more information, please visit LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact

ir@lifemd.com

Media Contact

press@lifemd.com

Tables to Follow

++++++

LIFEMD, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	June 30, 2026			December 31, 2025
ASSETS

Current Assets
Cash	$	25,141,615		$	36,786,318
Accounts receivable		11,256,158			9,305,277
Product deposit		243,759			320,217
Inventory, net		2,956,144			2,773,576
Other current assets		2,486,803			2,646,077
Total Current Assets		42,084,479			51,831,465

Non-current Assets
Equipment, net		2,035,475			2,444,717
Right of use assets, net		4,839,958			5,267,857
Capitalized software, net		10,734,486			10,604,946
Intangible assets, net		198,500			262,334
Total Non-current Assets		17,808,419			18,579,854

Total Assets	$	59,892,898		$	70,411,319

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities
Accounts payable	$	18,156,912		$	14,149,154
Accrued expenses		16,961,186			15,974,016
Current operating lease liabilities		699,511			642,422
Deferred revenue		10,791,221			10,807,773
Total Current Liabilities		46,608,830			41,573,365

Long-term Liabilities
Noncurrent operating lease liabilities		5,317,613			5,681,374
Total Liabilities		51,926,443			47,254,739

Commitments and Contingencies
Stockholders’ Equity
Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025		140			140
Common Stock, $0.01 par value; 100,000,000 shares authorized, 47,923,532 and 46,760,016 shares issued, 47,820,492 and 46,656,976 outstanding as of June 30, 2026 and December 31, 2025, respectively		479,235			467,600
Additional paid-in capital		253,763,518			251,455,616
Accumulated deficit		(246,112,737	)		(228,603,075	)
Treasury stock, 103,040 shares, at cost, as of June 30, 2026 and December 31, 2025		(163,701	)		(163,701	)
Total Stockholders’ Equity		7,966,455			23,156,580
Total Liabilities and Stockholders’ Equity	$	59,892,898		$	70,411,319

LIFEMD, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Telehealth revenue, net	$	47,281,085		$	49,018,882		$	97,444,041		$	99,906,781
Cost of telehealth revenue		5,284,323			6,838,703			11,209,822			14,975,164
Gross profit		41,996,762			42,180,179			86,234,219			84,931,617

Expenses
Selling and marketing expenses		28,035,947			22,151,114			57,910,807			44,424,036
General and administrative expenses		13,645,809			14,439,140			28,822,164			28,779,294
Other operating expenses		3,040,187			2,883,015			6,220,133			5,272,551
Customer service expenses		2,612,986			3,230,735			5,752,291			6,302,229
Development costs		1,791,434			1,823,061			3,587,497			3,682,110
Total expenses		49,126,363			44,527,065			102,292,892			88,460,220

Operating loss from continuing operations		(7,129,601	)		(2,346,886	)		(16,058,673	)		(3,528,603	)

Interest income (expense), net		45,660			(660,787	)		102,136			(1,124,425	)
Loss from continuing operations before income taxes		(7,083,941	)		(3,007,673	)		(15,956,537	)		(4,653,028	)

Income tax provision		-			-			-			-
Net loss from continuing operations		(7,083,941	)		(3,007,673	)		(15,956,537	)		(4,653,028	)

Net income from discontinued operations		-			1,893,084			-			3,886,506
Net loss		(7,083,941	)		(1,114,589	)		(15,956,537	)		(766,522	)

Net income attributable to noncontrolling interests of discontinued operations		-			505,075			-			1,036,920

Net loss attributable to LifeMD, Inc.		(7,083,941	)		(1,619,664	)		(15,956,537	)		(1,803,442	)

Preferred stock dividends		(776,562	)		(776,562	)		(1,553,125	)		(1,553,125	)

Net loss attributable to LifeMD, Inc. common stockholders	$	(7,860,503	)	$	(2,396,226	)	$	(17,509,662	)	$	(3,356,567	)

Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders
Continuing operations	$	(0.16	)	$	(0.09	)	$	(0.37	)	$	(0.14	)
Discontinued operations		-			0.03			-			0.07
Basic loss per share	$	(0.16	)	$	(0.05	)	$	(0.37	)	$	(0.08	)

Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders
Continuing operations	$	(0.16	)	$	(0.09	)	$	(0.37	)	$	(0.14	)
Discontinued operations		-			0.03			-			0.07
Diluted loss per share	$	(0.16	)	$	(0.05	)	$	(0.37	)	$	(0.08	)

Weighted average number of common shares outstanding:
Basic		47,788,194			44,401,531			47,563,376			43,772,151
Diluted		47,788,194			44,401,531			47,563,376			43,772,151

LIFEMD, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(7,083,941	)	$	(1,114,589	)	$	(15,956,537	)	$	(766,522	)
Less: Net income from discontinued operations		-			1,893,084			-			3,886,506
Net loss from continuing operations		(7,083,941	)		(3,007,673	)		(15,956,537	)		(4,653,028	)
Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities:
Amortization of debt discount		-			100,444			-			200,888
Amortization of capitalized software		1,713,679			1,586,322			3,388,532			3,115,702
Amortization of intangibles		31,917			23,500			63,834			30,167
Depreciation of fixed assets		292,787			175,523			582,245			330,884
Noncash operating lease expense		215,132			255,824			427,899			525,712
Stock compensation expense		790,112			2,094,614			2,239,017			4,643,142

Changes in Assets and Liabilities
Accounts receivable		(1,401,041	)		1,973,894			(1,950,881	)		1,513,946
Product deposit		87,766			(59,160	)		76,458			(210,237	)
Inventory		220,992			(283,658	)		(182,568	)		(453,997	)
Other current assets		1,368,328			522,068			159,274			824,289
Operating lease liabilities		(155,773	)		(68,507	)		(306,672	)		(148,306	)
Deferred revenue		(1,225,619	)		(2,783,497	)		(16,552	)		(2,586,163	)
Accounts payable		(3,496,210	)		8,573,302			4,007,758			8,487,929
Accrued expenses		1,716,223			(3,001,387	)		987,170			(5,260,493	)
Net cash (used in) provided by operating activities of continuing operations		(6,925,648	)		6,101,609			(6,481,023	)		6,360,435
Net cash provided by operating activities of discontinued operations		-			2,537,838			-			5,347,399
Net cash (used in) provided by operating activities		(6,925,648	)		8,639,447			(6,481,023	)		11,707,834

CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for capitalized software costs		(1,566,487	)		(2,060,313	)		(3,518,072	)		(3,947,128	)
Purchase of equipment		(67,825	)		(776,670	)		(173,003	)		(894,215	)
Net cash used in investing activities of continuing operations		(1,634,312	)		(2,836,983	)		(3,691,075	)		(4,841,343	)
Net cash used in investing activities of discontinued operations		-			(862,600	)		-			(1,725,578	)
Net cash used in investing activities		(1,634,312	)		(3,699,583	)		(3,691,075	)		(6,566,921	)

CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of debt instruments		-			(2,052,288	)		-			(2,052,288	)
Preferred stock dividends		(776,562	)		(776,562	)		(1,553,125	)		(1,553,125	)
Cash proceeds from exercise of options		-			-			80,520			-
Net cash used in financing activities of continuing operations		(776,562	)		(2,828,850	)		(1,472,605	)		(3,605,413	)
Net cash used in financing activities of discontinued operations		-			(276,119	)		-			(312,119	)
Net cash used in financing activities		(776,562	)		(3,104,969	)		(1,472,605	)		(3,917,532	)

Net (decrease) increase in cash		(9,336,522	)		1,834,895			(11,644,703	)		1,223,381
Cash at beginning of period		34,478,137			34,393,410			36,786,318			35,004,924
Cash at end of year		25,141,615			36,228,305			25,141,615			36,228,305
Less: Cash of discontinued operations at end of year		-			3,216,945			-			3,216,945
Cash of continuing operations at end of year	$	25,141,615		$	33,011,360		$	25,141,615		$	33,011,360

Cash paid for interest and taxes
Cash paid during the period for interest	$	-		$	625,818		$	-		$	1,219,568
Cash paid during the period for taxes	$	361,230		$	445,158		$	361,230		$	467,854

Non-cash investing and financing activities
Cashless exercise of options	$	-		$	501		$	-		$	1,062
Cashless exercise of warrants	$	-		$	3,901		$	-		$	3,901
Stock issued for debt conversion	$	-		$	1,000,000		$	-		$	1,000,000
Stock issued for asset acquisition	$	-		$	303,000		$	-		$	303,000

About the Use of Non-GAAP Financial Measures

To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of this financial measure enhances an investor’s understanding of our financial performance. We further believe that this financial measure is a useful financial metric to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.

Adjusted EBITDA is defined as net loss attributable to LifeMD, Inc. common stockholders before interest, taxes, depreciation, amortization, extraordinary litigation costs, severance and restructuring costs, acquisition expenses, insurance acceptance readiness expenses, preferred stock dividends, stock-based compensation expense, net income from discontinued operations and net income attributable to noncontrolling interests of discontinued operations. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to LifeMD, Inc. common stockholders, its most directly comparable GAAP financial measure.

We believe the above financial measure is commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.

Reconciliation of Net Loss Attributable to LifeMD, Inc. Common Stockholders to Adjusted EBITDA

(in whole numbers, unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Net loss attributable to LifeMD, Inc. common stockholders	$	(7,860,503	)	$	(2,396,226	)	$	(17,509,662	)	$	(3,356,567	)

Interest (income) expense (excluding amortization of debt discount)		(45,660	)		560,343			(102,136	)		923,537
Depreciation and amortization expense		2,038,383			1,785,345			4,034,611			3,476,753
Amortization of debt discount		-			100,444			-			200,888
Litigation costs ^(a)		386,366			486,462			1,047,941			739,659
Severance and restructuring costs		385,109			25,535			748,994			102,417
Acquisitions expenses		-			1,806,277			-			2,014,777
Insurance acceptance readiness		-			34,780			-			175,140
Preferred stock dividends		776,562			776,562			1,553,125			1,553,125
Stock compensation expense		790,112			2,094,614			2,239,017			4,643,142
Net income from discontinued operations		-			(1,893,084	)		-			(3,886,506	)
Net income attributable to noncontrolling interests of discontinued operations		-			505,075			-			1,036,920

Adjusted EBITDA	$	(3,529,631	)	$	3,886,127		$	(7,988,110	)	$	7,623,285

^(a) For the three and six months ended June 30, 2026, the Company included costs related to: (1) a class action complaint captioned Johnston v. LifeMD, Inc., et al., against the Company and certain executive officers alleging: (i) violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder by all defendants for making false and misleading statements; and (ii) violations of Section 20(a) of the Securities Exchange Act of 1934, as amended, by the individual officer defendants for violating their duty to disseminate accurate and truthful information, and (2) a heavily negotiated executive separation agreement. For the three and six months ended June 30, 2025, the Company included costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), and a heavily negotiated executive separation agreement.